The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Aug. 21, 2021
Applicant:

Duke University, Durham, NC (US);

Inventors:

Priya Kishnani, Durham, NC (US);

Baodong Sun, Durham, NC (US);

Dwight D. Koeberl, Durham, NC (US);

Assignee:

Duke University, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/47 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/277 (2006.01); A61K 31/352 (2006.01); A61K 31/355 (2006.01); A61K 31/385 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/522 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); A61K 31/575 (2006.01); A61K 31/7016 (2006.01); A61K 33/00 (2006.01); A61K 38/46 (2006.01); A61P 3/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/155 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/277 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/385 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/522 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/575 (2013.01); A61K 31/7016 (2013.01); A61K 33/00 (2013.01); A61K 38/465 (2013.01); A61K 38/47 (2013.01); A61P 3/00 (2018.01); C12Y 301/04012 (2013.01); C12Y 302/0102 (2013.01); C12Y 302/01022 (2013.01); C12Y 302/01045 (2013.01); C12Y 302/01049 (2013.01); C12Y 302/01076 (2013.01);
Abstract

The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.


Find Patent Forward Citations

Loading…